Sogroya (somapacitan-beco) is now approved as the first once-weekly, long-acting human growth hormone option for pediatric patients aged 2.5 years and older with growth failure associated with Turner ...
In the phase 3 TroFuse-015 study, sacituzumab tirumotecan significantly improved overall survival compared with physician’s choice of chemotherapy in pretreated advanced gastroesophageal ...
Reduction in perioperative hypotension seen among older adults undergoing noncardiac surgery under general anesthesia ...
Priority Review for the investigational CLDN18.2-directed antibody-drug conjugate is supported by phase 3 CLARITY-Gastric01 overall survival data, with an FDA decision expected in the second quarter ...
Intrathecal adrabetadex reduced the risk of death by 55% compared with weighted external controls in patients whose ...
The FDA has approved once-daily oral Infilbray (venglustat) as the first therapy indicated to treat neurological manifestations of type 3 Gaucher disease in adults and pediatric patients weighing at ...
HealthDay News — In July to August 2025, about one in 10 US adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research ...
Livsayis (cemdisiran) is the first siRNA therapy and first quarterly subcutaneous treatment for adults with anti-AChR antibody–positive generalized myasthenia gravis.
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
Oral remibrutinib demonstrated early and sustained efficacy through 52 weeks across 3 CIndU subtypes in the phase 3 RemIND ...
Five new treatments across rheumatology, nephrology, cardiology, dermatology, and endocrinology await FDA approval decisions before year-end 2026.